Nuvama identifies 10 stocks post Q2 earnings review
after close1 source ↓written by the desknot a recommendation
- with a target
- 18%
Brokerage firm Nuvama has reviewed Q2 earnings for 10 listed companies, assigning ratings based on performance. Buy ratings were maintained for Delhivery, Aurobindo Pharma, and others, while Reduce was given to Zydus Lifesciences and Birlasoft. The upside potential for Delhivery is noted at 18% with a target of ₹525.
This analysis may influence trading strategies as Nuvama adjusts estimates reflecting market conditions.
Not investment advice. For informational purposes only.